Energizer’s universal inductive charger to make retail debut
ST. LOUIS In response to consumers’ need for more power and convenient charging options for their smart phones and cell phones, Energizer has developed a universal inductive charger built with Qi technology.
Any device with 5 watts or less, regardless of manufacturer, now can be powered by Energizer’s inductive charger, which is designed to charge up to three devices at one time. In related news, Energizer also is developing a Qi sleeve and door for the iPhone and Blackberry, respectively.
"We believe that a universal standard is the future of charging, and by leading the way with one of the first Qi products — the Energizer inductive charger — we are meeting a clear need for a product that makes charging devices easier by eliminating cords and clutter," said Jim Olsen, VP marketing for Energizer North America. "This next-generation charger is a natural extension of an innovative product portfolio that brings more freedom for people to live and to work using power that’s reliable and convenient."
The Energizer inductive charger will be available at retail this October at a suggested retail price of $89.
Pfizer to acquire FoldRx
NEW YORK Pfizer announced Wednesday that it will acquire a privately held drug discovery and clinical development company.
FoldRx’s portfolio includes clinical and preclinical programs for investigational compounds to treat diseases caused by protein misfolding, which increasingly is recognized as an underlying cause in many chronic degenerative diseases. FoldRx’s lead product candidate, tafamidis meglumine, is an oral, disease-modifying therapy for TTR amyloid polyneuropathy (ATTR-PN), a progressively fatal genetic neurodegenerative disease, for which liver transplant is the only treatment option that currently is available, the companies said.
Financial terms of the agreement were not disclosed.
“By combining FoldRx’s proprietary expertise in identifying and developing treatments for protein misfolding diseases with Pfizer’s commercial, medical and regulatory expertise, and global strengths in patient services and reimbursement, we are taking a significant step toward potentially bringing, for the first time, a nonsurgical treatment option for underserved patients affected by the deadly disease ATTR-PN,” said Geno Germano, president and general manager of Pfizer’s specialty care business unit. “This transaction will add another important component to the growing portfolio of innovative in-line and investigational medicines for orphan and rare diseases within Pfizer’s specialty care business, and will complement the current and planned future research and clinical development taking place in Pfizer’s specialty care neuroscience disease area.”
Added FoldRx president and CEO Richard Labaudiniere, “Pfizer’s strong clinical and regulatory resources, global marketing reach and commitment to the treatment of rare diseases will significantly enhance the ability to pursue the goal of efficiently bringing tafamidis to all patients affected by this devastating neurodegenerative disease.”
Connoisseurs Products’ Diamond Dazzle Stik to make retail debut
NEW YORK Hitting retail shelves this fall is the new Diamond Dazzle Stik, which is a portable diamond cleaner that is sized to fit in a makeup bag or purse, from Connoisseurs Products.
The Diamond Dazzle Stik uses a twist-to-dispense click pen to deliver the cleansing solution to a flow-through brush. The brush has been engineered specifically to clean behind diamonds and other precious stones and their mountings.
The formula contains microfine cleansers and polishing agents combined with polymer. The polymer fills in fine scratches on the setting, increases the sparkle of the diamond and reduces future build-up of dirt.
To promote the launch, the manufacturer is launching a multipronged advertising program that includes sampling, social media efforts on Facebook, Twitter and YouTube, branded television spots and consumer contests.